- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
InMode Ltd(INMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for INMD
11/13/2026: INMD (1-star) is currently NOT-A-BUY. Pass it for now.
InMode Ltd is a medical technology company specializing in energy-based minimally invasive and non-invasive aesthetic treatment solutions. The company's core strengths include proprietary radio frequency technologies like Morpheus8, exceptional gross margins, and a debt-free balance sheet with solid cash generation. Its primary growth opportunity centers on expanding aesthetic applications to address skin laxity driven by widespread weight-loss drug adoption. Key risks include revenue concentration in capital equipment, geopolitical manufacturing exposure in Israel, and sensitivity to macroeconomic cycles affecting elective procedures. The stock suits value-oriented investors seeking high profitability, while market participants should monitor quarterly equipment sales trends and international adoption metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While InMode features high historical profitability, recent top-line growth has moderated compared to its hyper-growth phase. |
| Momentum investor | Strong fit while signal remains positive | Momentum fit is conditional on a positive upturn signal and renewed short-term price momentum. |
| Value investor | Strong fit | InMode trades at a low price-to-earnings multiple backed by significant cash reserves and strong free cash flow conversion. |
| Dividend investor | Weak fit | The company does not pay a regular dividend, focusing instead on share buybacks and organic cash retention. |
| Low-risk investor | Mixed fit | Small-cap equity volatility and elective healthcare exposure introduce risk despite a debt-free balance sheet. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Small-cap aesthetic device stocks frequently experience sharp price fluctuations based on macroeconomic sentiment. |
| Valuation risk | Low | InMode trades at modest earnings multiples relative to its historical averages and cash levels. |
| Competition risk (aesthetic device competition) | Medium | Intense competition from emerging laser and RF device manufacturers could pressure pricing power. |
| Business quality | Strong | The company maintains exceptional gross and operating margins backed by proprietary technology. |
| Dividend income | Low / none | Income-focused investors receive no regular cash payout from the stock. |
| Execution risk | Medium | Sustaining physician adoption and successfully commercializing new product lines is critical for future performance. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 763.61M USD | Price to earnings Ratio 11.15 | 1Y Target Price 14.67 |
Price to earnings Ratio 11.15 | 1Y Target Price 14.67 | ||
Volume (30-day avg) 563.6K shares | Beta 1.96 | 52 Weeks Range 12.72 - 16.67 | Updated Date 11/15/2026 |
52 Weeks Range 12.72 - 16.67 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.19 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -47.92% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Capital Equipment | Sales of multi-application aesthetic platforms like Morpheus8, BodyTite, and EvolveX to dermatology and plastic surgery practices. | This is the primary upfront revenue engine when clinics purchase new treatment systems. |
| Consumables and Services | Sales of single-use treatment tips, treatment cartridges, and post-warranty service contracts. | Provides recurring revenue streams as physicians perform repeat procedures for patients. |
| Geographic Distribution | Direct sales in North America and Europe, supported by global international distribution partners. | North America serves as the primary profit driver while international markets offer additional expansion upside. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-11 | When Before Market | Estimate 0.322 | Actual 0.37 |
Profitability
Profit Margin 19.95% | Operating Margin (TTM) 17.95% |
Management Effectiveness
Return on Assets (TTM) 5.68% | Return on Equity (TTM) 11.42% |
Valuation
Trailing PE 11.15 | Forward PE 9.35 | Enterprise Value 254.46M | Price to Sales(TTM) 2.04 |
Enterprise Value 254.46M | Price to Sales(TTM) 2.04 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA 3.82 | Shares Outstanding 57.54M | Shares Floating 48.01M |
Shares Outstanding 57.54M | Shares Floating 48.01M | ||
Percent Insiders 13.22 | Percent Institutions 56.84 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

